13.38
-0.15%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Zhejiang Hisun Pharmaceutical Co
Its shares trade on Shanghai under the ticker 600267.SS. It has been listed since 25 July 2000. In the fiscal year to 31 December 2025, it reported revenue of CN¥10.55bn and net income of CN¥540.7m. At that date it held total assets of CN¥15.05bn and shareholders' equity of CN¥8.61bn.
Zhejiang Hisun Pharmaceutical Co., Ltd. engages in the research & development, manufacture, and sale of pharmaceutical products as well as veterinary medicines. The company is headquartered in Taizhou, Zhejiang. The company went IPO on 2000-07-25. The firm's bulk pharmaceutical chemicals mainly include antineoplastic drugs, cardiovascular drugs, anti-infection drugs, endocrine control drugs, anthelmintic, as well as animal remedies, among others. The firm is also engaged in the sales of drugs manufactured by other companies. The firm distributes its products in domestic markets and to overseas markets.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 25 Jul 2000
- Employees
- 8,325
- Website
- hisunpharm.com ↗
Leadership
Pay as last reported
- Mr. Weihong XiaoPresident, Director, since 2023CN¥869,500
- Mr. Jiaqiu DuSenior Vice President, Director, since 2019CN¥2.1m
- Mr. Hongshun JinSenior Vice PresidentCN¥1.1m
- Mr. Zhiqing YangSenior Vice PresidentCN¥1.4m
- Mr. Xifei ShenSecretary of the BoardCN¥825,500
- Mr. Rongfu FeiDirector
- Mr. Baichao ZhengDirector
- Mr. Lirong YangIndependent DirectorCN¥96,000
- Mr. Jiayi ZhaoIndependent DirectorCN¥96,000
- Ms. Huali ZhouIndependent DirectorCN¥96,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 81
- Environment
- 79
- Social
- 99
- Governance
- 64
- Direct emissions (scope 1)
- 104,873.76 t
- Energy emissions (scope 2)
- 238,151.47 t
- Women in the workforce
- 48.13%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Zhejiang Hisun Pharmaceutical employs 8,325 full-time employees in the Health Care sector.
- The company manufactures antineoplastic drugs and cardiovascular drugs for domestic and overseas markets.
- Zhejiang Hisun Pharmaceutical distributes veterinary medicines and animal remedies globally.
Weaknesses
- Zhejiang Hisun Pharmaceutical's bulk pharmaceutical chemicals include anti-infection drugs and endocrine control drugs.
- The company's business description mentions sales of drugs manufactured by other companies.
- Zhejiang Hisun Pharmaceutical's headquarters is in Taizhou, Zhejiang, China.
Opportunities
- Zhejiang Hisun Pharmaceutical can expand its sales of antineoplastic drugs in overseas markets.
- The firm's distribution of animal remedies offers opportunities in veterinary medicine markets.
- Zhejiang Hisun Pharmaceutical can leverage its 8,325 employees for R&D growth in Pharmaceuticals.
Threats
- Zhejiang Hisun Pharmaceutical faces competition from other pharmaceutical manufacturers in China.
- The company's reliance on domestic markets may limit growth potential.
- Zhejiang Hisun Pharmaceutical's business is subject to regulatory changes in the Health Care sector.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.